Fig. 2: h11B11 effectively inhibits original coronaviruses and novel lineages of SARS-CoV-2 in vitro. | Nature Communications

Fig. 2: h11B11 effectively inhibits original coronaviruses and novel lineages of SARS-CoV-2 in vitro.

From: A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants

Fig. 2

a, b Inhibiting potencies of MAb to original SARS-CoV, SARS-CoV-2, or epidemic SARS-CoV-2 variant pseudovirus were evaluated in a luciferase reporter assay. IC50 was calculated by fitting the relative fluorescence intensity of host cells from serially diluted antibodies to a sigmoidal dose–response curve. c h11B11 was tested against 34 pseudotyped SARS-CoV-2 variants emanated from GISAID. d IC50 to live SARS-CoV-2 was fit the CPE from serially diluted antibody to a sigmoidal dose–response curve after 3 days of incubation. The values in the x-axis of a, b, and d represent concentrations of the antibody. IC50 in (a–d) represents mean ± SEM (standard error of the mean) of triplicated independent assessments.

Back to article page